Rigel Pharmaceuticals – Biotech Gem with Catch-Up Potential

Rigel is rapidly growing, achieving stable profits and is being traded at a price-to-earnings ratio (P/E) of only 7, significantly below industry standards – a clear indication of catch-up potential. With a 76% revenue growth in the last quarter and increasing demand for all three core medications, Rigel is evolving from a niche biotech company into a profitable growth stock. Biotech stocks have been among the fastest-growing US equities for weeks. Despite operational progress, the sector has lagged behind the overall market rally so far...